Viking Therapeutics Announces Completion of Enrollment in Phase 2b VOYAGE Study of VK2809 in Patients with Biopsy-Confirmed Non-Alcoholic Steatohepatitis (NASH)
Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Evaluating Range of VK2809 Doses for up to 52 Weeks; Data for Primary Endpoint Expected…